Cloud computing platform for virtual screening and drug discovery.
Cloud computing platform for virtual screening and drug discovery.
批准号:
8647456
负责人:
Robert J Dockhorn
金额:
$68.13万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-01 至 2016-02-29
关键词:
AchievementAlgorithmsBackBindingBinding SitesBiologicalBiotechnologyBusinessesChemical StructureChemicalsClientCloud ComputingCollaborationsComputer SimulationComputer softwareData AnalysesDatabasesDevelopmentDiseaseDockingDrug IndustryDrug TargetingEnvironmentEnzymesEvaluationGoalsHousingImageryInformaticsInternetLearningLibrariesLigandsMediationModelingModificationMolecular WeightNatureOccupationsOnline SystemsOutcomePC3 cell linePerformancePhaseProcessPropertyPublic HealthResearchResearch InfrastructureResearch PersonnelScreening ResultSecureSecuritySecurity MeasuresServicesSmall Business Innovation Research GrantSpecific qualifier valueStagingStructureSystemTechniquesTechnologyTestingTimeLineUniversitiesValidationVendorWorkanalytical toolbasechemical propertycluster computingcomputer infrastructurecomputerized toolscomputing resourcescostcost effectivedrug candidatedrug discoveryencryptionhealth economicsimprovedmacromoleculenovel therapeuticspublic health relevancereceptorscreeningsmall molecule librariestherapeutic targettoolvirtualweb based interfaceweb interfaceweb services
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract:
This is a Phase II application for continued development of the Chemalytics Platform, a scalable computational
infrastructure to enable virtual screening of chemical libraries using the Amazon EC2 cloud computing
environment and automated docking tools.
Structure-based virtual screening is an important tool in the drug discovery process (1-7). The use of
computational tools has allowed for the screening of large libraries of chemical compounds to identify putative
ligand-receptor interactions (8-9). The identification of valid targets and therapeutic compounds has long-term
importance both to the public health and the economic strength of the pharmaceutical industry.
Receptor-based virtual screening (VS) is a technique in which computational tools are used dock small
molecular weight compounds into a protein receptor or enzyme. This technique is most often used in drug
discovery, where a large library of chemical structure can be docked and scored to assess the potential if a
compound to bind to a drug target. However, high-throughput virtual screening is computationally intensive,
and the cost of building, maintaining, and managing a dedicated computing cluster limits access to these
technologies to large universities and commercial enterprises. Internet-based computing, also known as cloud
computing, is a business service model in which computational resources are accessed on-demand as
needed, and is affordable, scalable, and secure.
We have completed the Phase I goals of a building a web-based interface to manage users, jobs, and display
results from virtual docking screens. The current system employs the Amazon EC2 environment and has been
successfully used to screen chemical libraries of more than 2.3 million structures in an economical and rapid
fashion. In collaboration with a biotechnology partner, we are now pursuing chemical leads which are active
against prostate cancer cell lines.
In this phase we will expand the capabilities of the current system through the following technical
achievements: (1) integration of additional chemical libraries and library filtering tools to focus search space
prior to docking; (2) enhancement of end user ability to evaluate results through integration of data analysis
and visualization tools; (3) validation of this approach through analysis of screening results with our
collaborators and commercial partners.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金